Investing in Reata Pharmaceuticals Inc. [RETA]: What You Must Know


Following these proceedings, Guggenheim initiated its Reata Pharmaceuticals Inc. [RETA] rating to a Buy in a research note published on Tuesday, October 19, 2022; the price target was $75. PT values the company’s stock at a premium of 58.44 to its Tuesday closing price. SVB Leerink also remained covering RETA and has decreased its forecast on December 09, 2021 with a “Mkt perform” recommendation from previously “an Outperform” rating. Robert W. Baird revised its rating on December 09, 2021. It rated RETA as “a Neutral” which previously was an “an Outperform”.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Price Performance Review of RETA

On Tuesday, Reata Pharmaceuticals Inc. [NASDAQ:RETA] saw its stock jump 1.04% to $31.17. On the same session, the stock had its day’s lowest price of $29.03, but rose to a high of $38.94. Over the last five days, the stock has lost -24.69%. Reata Pharmaceuticals Inc. shares have fallen nearly -17.95% since the year began. Nevertheless, the stocks have risen 19.29% over the past one year. While a 52-week high of $51.98 was reached on 02/08/23, a 52-week low of $18.47 was recorded on 02/27/23. SMA at 50 days reached $40.45, while 200 days put it at $32.92. A total of 5.85 million shares were traded, compared to the trading of 2.23 million shares in the previous session.

Levels Of Support And Resistance For RETA Stock

The 24-hour chart illustrates a support level at 27.15, which if violated will result in even more drops to 23.14. On the upside, there is a resistance level at 37.06. A further resistance level may holdings at 42.96. The Relative Strength Index (RSI) on the 14-day chart is 36.56, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -7.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.91%. Stochastics %K at 28.09% indicates the stock is a holding.

How much short interest is there in Reata Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Reata Pharmaceuticals Inc. stocks on Jan 12, 2023, growing by 0.82 million shares to a total of 8.14 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 7.32 million shares. There was a rise of 10.07%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 39.71% of the overall stock float, the days-to-cover ratio (short ratio) rose to 16.51.

Reata Pharmaceuticals Inc. [RETA] – Who Are The Largest Shareholders?

In filings from CPMG, Inc., it is revealed that the company now owns 2,896,901 shares, or roughly 9.13% of the outstanding RETA shares. Additionally, The Vanguard Group, Inc. increased 1.97% of its stake after which the total value it holdings stand at $114,279,495, while First Light Asset Management LLC added 95.50% of its stake to hold $89.37 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 173,985 shares of Reata Pharmaceuticals Inc., while Fred Alger Management LLC bought 897,481 shares. At present, Wellington Management Co. LLP is holding 1,507,882 shares valued at $65.34 million. DWS Investment GmbH owned 1,467,498 shares of the company at the time of its most recent 13F filing, worth $63.59 million.

According to FactSet, Reata Pharmaceuticals Inc.’s share price will average $62.60 in the next year, based on opinions of analysts polled by the firm. This is up nearly 84.76 percent from its previous closing price of $30.85. Analysts expect Reata Pharmaceuticals Inc. stock to reach the higher price of $117.00, while the lowest price estimate is $35.00. However, 10 analysts have rated RETA stock as an Overweight in their predictions for 2023. The most recent change occurred on May 24, 2021 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $236 price target.


Please enter your comment!
Please enter your name here